MEDTECH

Aesthetics Biomedical® Announces Collaboration with U.S. Dermatology Partners Offering Consumers Luxury Experiential Aesthetic Treatments

Aesthetics Biomedical® Inc. | October 07, 2021

Aesthetics Biomedical® Inc. (ABM), is pleased to announce their long-term partnership with U.S. Dermatology Partners, the largest physician-led dermatology practice in the United States.

With years of experience and more than 90+ locations throughout Arizona, Colorado, Kansas, Maryland, Missouri, Oklahoma, Texas, and Virginia, U.S. Dermatology Partners combines the personal level of care found in private dermatology practices with the benefits of a network of physician experts working closely together. As a result, U.S. Dermatology Partners can provide premier medical and cosmetic dermatological care, along with the latest technology, treatments, and management support.

Striving to innovate, generate solid clinical and laboratory research, and to enrich the physician as well as the patient experience are principles that Aesthetics Biomedical® was founded on. It is these foundational principles that have led to our synergy with U.S. Dermatology Partners.

- Chief Executive Officer & Founder, MaryAnn Guerra

U.S. Dermatology Partners, a pinnacle network of specialty experts found a lifetime partner in excellence and innovation with Aesthetics Biomedical®. Beginning in 2021, U.S. Dermatology Partners installed Vivace® into four initial practices. A pilot project between the two organizations launched the partnership that resulted in over 170 consumer treatments being sold within the first four weeks. U.S. Dermatology Partners and ABM marketed the Vivace Experience® concept with the objective of delivering an immediate ROI supporting the purchase of the initial device for the organization. Vivace® is a primary driver expected to positively impact U.S. Dermatology Partners' market growth exponentially and rapidly, already generating significant revenue in six locations across the US, in under six (6) months. Having access to ongoing knowledge and clinical data is critical to U.S. Dermatology Partners physicians who are committed to continuous and consistent superior patient care.

 U.S. Dermatology Partners is thrilled to be collaborating with Aesthetics Biomedical® to bring the Vivace Experience® to our patients and our growing network to Aesthetics Biomedical®. We expect the innovative technology and outstanding results that Vivace offers will be well-received by both our physicians and patients and will provide another opportunity to deliver superior care to the communities we serve.

- U.S. Dermatology Partners Chief Executive Officer Paul Singh

Vivace® is a minimally invasive, FDA-cleared, radiofrequency microneedling treatment that stimulates the natural production of collagen and has been shown by physicians to be effective in alleviating facial wrinkles, fine lines, and tightening the face and neck. Aesthetics Biomedical's Vivace® is currently offered in multiple U.S. Dermatology Partners practices across 50% of the markets nationwide with rapid expansion plans in Q4. ABM will help to drive U.S. Dermatology Partners's practice success with superior technology, devices, and products supported by science, customer-focused market recognition, rigorous and continuing education, and strong continuous return on investment.

Both organizations are aligned in their commitment to excellence and share a common goal for elevating the consumer experience at the forefront of the partnership.

ABOUT AESTHETICS BIOMEDICAL
Aesthetics Biomedical® Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical's innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network, and the aesthetic arena, creating novel patient treatment experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. 

ABOUT U.S. DERMATOLOGY PARTNERS
As one of the largest physician-owned dermatology practices in the country, U.S. Dermatology Partners patients not only have access to general medical, surgical, and cosmetic skin treatment through its coordinated care network, but also benefit from the practice's strong dermatology subspecialty thought leaders and medical advisory board. To be the best partners to its patients, U.S. Dermatology Partners is fervently focused on providing the highest level of patient-first care, and its team, therefore, includes recognized national leaders in areas such as clinical research, psoriasis, and Mohs Surgery.

Spotlight

Molecular Genetics Biotechnology


Other News
DIAGNOSTICS

RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies

RQ Bio | May 17, 2022

RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio's existing mAbs against SARS-CoV-2. The Company, which is headquartered in London, is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging and new viral infections. To maximise and accelerate patient impact, the company will continue to be supported by its collaborations with its scientific co-founders, the University of Oxford and leading UK medical research charity LifeArc. Professor Gavin Screaton, Head of the Medical Sciences Division at the University of Oxford, will continue to advise in his capacity as scientific and medical co-founder, as will Clare Terlouw, Head of LifeArc Ventures and UK BIA board member, as a member of the Board of Directors. Our vision is to build on our successful debut with neutralising antibody therapy for SARS-CoV-2 and develop innovative medicines to address current and evolving unmet needs in other viral infectious diseases, By combining our expertise and innovative excellence in core areas we have created a smarter approach to antibody generation making us uniquely positioned to deliver fast patient impact." Hugo Fry, CEO of RQ Bio. LifeArc is committed to backing leading UK academics and scientists, and we were inspired to fund RQ Bio because of the exceptional group of founders who are so passionately dedicated to finding new treatments and preventative therapies in areas of high unmet patient need, LifeArc provided support from across the Charity, including the venture team, scientific labs and other in-house experts to help RQ Bio execute on its business plan, and we look forward to further supporting RQ Bio as it becomes a world-leading infectious disease company." Clare Terlouw, Head of LifeArc Ventures. About RQ Bio RQ Bio's mission has been to develop medicines based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from current and future variants of viral infections. RQ Bio has achieved this by combining innovative excellence in core areas to create a smarter approach to antibody generation. RQ Bio has multiple sources of leads and a deep collaboration with the University of Oxford. RQ Bio was founded by scientific experts previously involved with the UK BIA Antibody Taskforce, which worked to build a community of infectious disease antibody experts focussed on the development of rapid and efficient delivery of highly potent neutralising antibodies to help support the UK COVID-19 response. About AstraZeneca Licensing Deal Under the terms of the agreement, RQ Bio has granted AstraZeneca an exclusive worldwide licence to develop, manufacture and commercialise RQ Bio's exisiting early stage mAbs against SARS-CoV-2 and a right of first refusal to take an exclusive licence in respect of any additional mAbs against SARS-CoV-2. RQ Bio will receive upfront and milestone payments of up to $157 million and will be eligible to receive single digit royalties on sales. The successful licensing deal was supported by Oxford University Innovation (OUI), a wholly-owned subsidiary of the University of Oxford that manages the University's technology transfer and consulting activities, who worked efficiently and creatively with all parties on the corresponding technology licences and the filing of intellectual properties.

Read More

INDUSTRIAL IMPACT

Angel Yeast Partners with PhaBuilder to Open PHA Factory

Angel Yeast | July 27, 2022

Angel Yeast a globally listed yeast and yeast extract manufacturer, has inked an agreement with Bejing PhaBuilder Biotechnology Co., Ltd in Yichang, Hubei province to build a large manufacturing base for polyhydroxyalkanoates (PHA) in the city. The pair will set up a joint venture company to drive the application of synthetic biology in the biotechnology industry. PHA is a polyester produced naturally by microorganisms. The biodegradable and biocompatible properties of PHA make it highly sought-after in fields such as biomedical material and biodegradable packaging material. "This collaboration with PhaBuilder marks a milestone and a significant step forward for Angel Yeast in synthetic biology. At Angel Yeast, we are very keen on innovation and exploration of new landscapes in the industry. This project is also part of our efforts to be an international and professional biotechnology company," Tao Xiong, chairman of Angel Yeast He added that the partnership is expected to forge a new venture in bioeconomy, fuel innovation in synthetic biology, and drive the expansion of the global market. Guoqiang Chen, the founder of PhaBuilder, added that by working with Angel Yeast on the initiative, major inroads have been made in converting technology breakthroughs into industrial programs for synthetic biology. "The new production line of PHA with the capacity of 30,000 tons will certainly bring more advanced technologies, new services and products for the industry and consumers. It will also create a 'greener' lifestyle. We are thrilled to see it happen," said Chen. In addition to synthetic biology, Angel Yeast has also been exploring cutting-edge development in biological agriculture. According to the company, it will be engaged in a project to produce animal feed through biological fermentation. Angel Yeast will invest some 120 million yuan to build the manufacturing center with an annual capacity of 50,000 tons. The project is estimated to start in August 2022 and to be completed in September the next year. One highlight of the project is that it uses Distillers' Dried Grains with Solubles (DDGS) as one raw material to produce yeast culture products. As a new category, yeast culture products will diversify the company's animal nutrition products lineup. About Angel Yeast Founded in 1986, Angel Yeast Co., Ltd specializes in the production of yeast and yeast derivatives. Its product range includes baker's yeast and ingredients, Chinese dim sum and seasoning, savory yeast extract, human health, animal nutrition, plant nutrition, distilled spirits and biofuels, microbial nutrition, and enzymes.

Read More

RESEARCH

Lunaphore and Indica Labs announce partnership to provide complete technology solution for spatial biology and image analysis

Indica Labs | May 13, 2022

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Indica Labs, a leading provider of computational pathology software and services, today announced a partnership to co-market an end-to-end solution that combines Lunaphore's flagship COMET™ spatial biology platform and Indica's HALO® and HALO AI™ digital pathology image analysis software. Lunaphore's COMET™ platform provides superior multiplex staining and image acquisition capabilities facilitating the automated detection of up to 40 separate spatial markers per tissue slide without human intervention. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free antibodies and is designed to provide researchers with flexibility for their workflow. COMET™ has a wide range of research applications across immuno-oncology, neuroscience, and infectious diseases. Indica Labs' industry-leading HALO® and HALO AITM software enable fast, AI-based quantitative analysis of whole slide images. In combination with the COMET™ platform, the HALO Highplex FL module allows researchers to quantify an unlimited number of fluorescent markers and cell phenotypes defined by their biomarker expression. HALO Spatial Analysis and HALO AI deep learning classifiers are used in combination with Highplex FL to explore the distribution and spatial relationships between different cell phenotypes in the context of the tissue, such as tumor and immune cells. This additional spatial data is particularly important in immuno-oncology and neuroscience disease research. We are excited to partner with Lunaphore to address the growing needs of our research customers for highly multiplexed assays, Combining Lunaphore's superior multiplexing technologies upstream with our powerful AI-based analysis downstream, together we provide a streamlined workflow for high dimensional imaging and image analysis." Steven Hashagen, CEO of Indica Labs. Our partnership with Indica Labs is another key aspect of our strategy to combine our COMET™ technology with industry-leading image analysis technologies, Indica Labs' solutions are used by a large set of researchers in the field, thanks to their ease of use and analysis capabilities. Combining Indica's solutions with the class-leading capabilities of COMET™ will help us pursue our shared goal of making tissue image analysis easier and more accessible to labs around the world." Deborah Heintze, Chief Marketing Officer of Lunaphore. About Lunaphore Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. About Indica Labs Indica Labs is the world's leading provider of computational pathology software and image analysis services. Our flagship HALO® and HALO AI™ platform facilitates quantitative evaluation of digital pathology images. HALO Link™ facilitates research-focused image management and collaboration while HALO AP® enables collaborative clinical case review. Our Pharma Services team leverages all our image analysis platforms to partner with you to advance tissue-based research, clinical trials, and diagnostics.

Read More

INDUSTRIAL IMPACT

Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

Celyad Oncology | August 01, 2022

Celyad Oncology SA a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the CYAD-101-002 Phase 1b trial after the Company made changes to the eligibility criteria for the trial. “We are pleased that the FDA lifted the clinical hold on this trial. We remain confident in the potential development of not only the candidate itself, but the continued development with our proprietary TIM technology. CYAD-101 is currently our only clinical candidate co-expressing NKG2D and TIM, and we hope to continue to showcase our expertise with our non-gene edited technologies and explore additional opportunities to utilize NKG2D in allogeneic CAR T,” Dr. Charles Morris, Chief Medical Officer of Celyad Oncology As previously disclosed, on February 28, 2022, the Company announced that it was voluntarily pausing the CYAD-101-002 trial to investigate reports of two fatalities in the study. The trial was subsequently put on clinical hold in March 2022 by the FDA. About Celyad Oncology Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region to support the advancement of its CAR T cell therapy programs.

Read More